Global private equity and venture capital news and research

Posts Tagged ‘Alta Partners’

9 April 2015

Venture capital-backed protein biologics company aTyr Pharma files for IPO

download (4) Rare disease specialist aTyr Pharma, whose venture capital backers include Alta Partners, Cardinal Partners and Domain Associates, has filed for an IPO.

20 June 2014

Venture capital-backed Zafgen secures $96m via IPO

obb Venture capital-backed biopharmaceutical company Zafgen has raised $96m via its IPO on the Nasdaq exchange.

21 May 2014

Venture capital-backed Kite Pharma files for IPO

cancer band pink_sq Venture capital-backed biopharmaceutical startup Kite Pharma has filed for an IPO.

4 December 2013

Biotech company Zafgen raises $45m Series E

biotech_lrg Biopharmaceutical business Zafgen has raised $45m in a Series E round to fund the development of its obesity therapeutic beloranib.

30 October 2013

Venture-backed cancer treatment business Immune Design scores up to $49m in Series C round

biomed_lrg Venture capital-backed biotech business Immune Design has collected up to $49m in Series C financing as it continues to develop immune-based therapies for cancer and other chronic conditions.

12 June 2013

Swift part-exit for Longitude as Esperion eyes IPO weeks after investment $

Venture investors in biopharmaceutical business Esperion Therapeutics are preparing to sell down their stakes through an IPO just weeks after the company completed a $33m preferred financing round.

27 December 2012

Domain, Alta return to Lithera in $20.6m equity round

Life sciences-focused venture firms Domain Associates and Alta Partners have re-upped their investments in Lithera as part of a $20.6m equity financing.

17 December 2012

Novo Ventures leads $32m financing for biotech company Allakos

virus2_sq Denmark-based Novo Ventures has led a $32m Series A preferred stock financing round for antibody-focused biotechnology company Allakos.

29 October 2012

Texas pharmaceutical company ZS Pharma closes $46m venture round

blood_vein_170sq Texas-based pharmaceutical company ZS Pharma has raised $46m to advance the development of ZS-9, a crystal form of zirconium silicate designed to treat patients with kidney and liver disease.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016